[ad_1]
New Years Eve Special Session of the 2021 Strategy Conference: December 31 (Thursday) 20: 00-1 January (Friday) 00:30 New Years Eve Special Session, Champion Fund Manager ABC-CA, Zhao Yu, China Merchants Liquor Fund Manager Hou Ha, ICBC Credit Suisse Unique Item, Private Equity Celebrities Wang Qing, Chen Yu, Li Jinlong etc, Have a Different New Years Eve with You!Click to see
Vaccine stocks soared! China’s new coronavirus vaccine is officially on the market, free for everyone! Production capacity will exceed 1 billion doses next year.
Zhang Xue Shanghai Securities News
On December 31, the Joint Prevention and Control Mechanism of the State Council was published. Sinopharm’s China Bio-New Crown Inactivated Vaccine has been approved by the State Food and Drug Administration for conditional inclusion.
The data shows that the protection rate is 79.34%, achieving the unit of safety, effectiveness, accessibility and affordability, and complying with the relevant standards of the World Health Organization and the National Food and Drug Administration. In the future, the durability and protective effect of the immunity of the vaccine should be continuously observed.
On December 30, Sinopharm China Bio-Beijing Company released the data from the interim analysis of the phase III clinical trial of the novel coronavirus inactivated vaccine. The data results show that the safety of the new coronavirus inactivated vaccine from Sinopharm China Bio-Beijing Company is good after vaccination. After two doses of vaccination according to the immunization schedule, the vaccinated vaccine group produced antibodies with high titers and the positive conversion rate of neutralizing antibodies was 99.52%. , The protective efficacy of the vaccine against the disease (COVID-19) caused by the new coronavirus infection is 79.34%.
Sinopharm China Biotech stated that the data results comply with the relevant technical standards of the World Health Organization and the relevant standards in the “Guidelines for Clinical Evaluation of New Preventive Coronavirus Vaccines (Assay)” issued by the State Administration of Food and Medicines.
According to Wu Yonglin, President of China Biotech, on December 9 and 13, the United Arab Emirates and Bahrain respectively reviewed and approved the official registration and marketing of the inactivated Sinopharm China Bio-New Crown vaccine inactivated according to technical standards. relevant from the World Health Organization.
Today’s press conference also gave answers to the question that everyone is concerned about in general: “Can the new coronavirus vaccine that is conditionally listed this time be able to cope with the mutated virus?”
According to Xu Nanping, Vice Minister of the Ministry of Science and Technology, the result of an expert investigation is that there is currently no evidence that the observed variation has a substantial impact on the effectiveness of the vaccine. The scientific research team has a special plan , organized superior national forces and established several research groups to conduct special research on virus mutation, detection reagents, drug development, and the effects of using vaccines to deal with the effects of virus mutation on the use of vaccines. Influence, thereforeCommon peopleProvide safe, effective and accessible vaccines.
The new epidemic of corona pneumonia that has spread throughout the world has made vaccine research and development the focus of global attention.
The measurement of a vaccine depends on its performance in multiple aspects, with safety, effectiveness, accessibility and adaptability all worthy of attention. In addition, it must meet the requirements of sufficient production, convenient transportation and storage, and affordable final prices.
In terms of safety, among the new corona vaccines that have published data, Sinopharm China Biotech has selected the route of inactivated vaccine technology.
The data show that inactivated vaccines have mature technical pathways and high safety. They have been validated in the market for decades. In immunization programs around the world, inactivated vaccines represent a large proportion and are widely used in the prevention of various diseases. Long-term research and clinical use have verified that inactivated vaccines are very safe and effective.
In terms of effectiveness, China Biotech President Wu Yonglin said that according to data from Phase I and II studies of the new inactivated corona vaccine, antibodies can still remain at a high level for more than 6 months. The results of the clinical trial data show that the results of the protection data have reached the predetermined objective and have met the marketing requirements. Currently, clinical studies in China, the United Arab Emirates, Bahrain and other countries are still ongoing, and the persistence of antibodies will continue to be observed.
In terms of protection, at present, the rate of positive conversion of “neutralizing antibodies” that can eliminate the virus in the body after all approved vaccinations is above 90%, which means that, in theory, almost everything the world can develop resistance after vaccination. Antibodies against viruses. The positive conversion rate of the neutralizing antibody of the Sinopharm Group China Biologics inactivated vaccine is 99.52% and the protective effect of the vaccine against the disease caused by the novel coronavirus infection (COVID-19) is 79.34 %.
In terms of accessibility, the storage conditions of Sinopharm Sinopharm inactivated vaccines are stored and transported in the dark at 2-8 ° C and are stable for 24 months. The new national crown vaccine has obvious advantages in storage and transportation. The storage and transport conditions of the cold chain (2-8 ° C) meet the standards of the global cold chain system and the national conditions of most countries. This greatly reduces storage and transportation requirements and improves the accessibility of the vaccine. Sex.
Regarding the production capacity, the high-grade biosafety production workshops of the new corona inactivated vaccines built by Sinopharm Group Sino Biotech in Beijing and Wuhan are expected to have a production capacity of more than 1 billion doses next. year, which is equivalent to international production capacity.
Regarding prices, Zeng Yixin, deputy director of the National Health Commission and head of the vaccine research and development team of the Joint Prevention and Control Mechanism of the State Council, said that the new coronavirus vaccine should delivered free of charge to all people.
In terms of adaptability, according to public data, Sinopharm China Bio-New Crown Vaccine Phase III clinical enrollment of 60,000 people, volunteers covering 125 nationalities, the number of people covered and their respective countries is the first in the world, and the rank of vaccination age is 18 to 60 years. Years, showing good adaptability.
According to Zeng Yixin, to prevent the outbreak of the epidemic in winter and spring, but also to effectively protect cold chain logistics personnel, customs border inspection personnel, disease control medical personnel, personnel of Public transportation, as well as farmers markets, seafood markets, and other infection risks are relatively high. For the population, the vaccination of key populations in China was officially launched on December 15.
In the past two months, cumulative vaccination of key populations across the country has exceeded 3 million doses. Among them, cases of mild fever are less than 0.1%, and the incidence of more serious adverse reactions, such as allergic reactions, is approximately two per million, which fully demonstrates that the vaccine is safe.
The research and development of vaccines in China have made tremendous strides and advances. From the comprehensive assessment of various aspects of performance, in this new examination of the corona pneumonia epidemic, the research and development of China’s new coronavirus vaccine has produced an excellent answer sheet, that is most important to the people of the country and the world. Give the best New Year’s gift of 2021.
Massive information, accurate interpretation, all in the Sina Finance APP
Editor in Charge: Chang Fuqiang
